# US 10,117,913 B2 · Antigens of Pneumocystis murina and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,913 B2
- Document ID: US10117913B2
- Status: Granted
- Kind: B2
- Application number: 15/305,190
- Filed: 2015-05-04
- Published: 2017-02-16
- Granted: 2018-11-06
- Earliest claimed: 2014-05-05
- Assignees: Board of Supervisors of Louisiana State University; University of New Orleans
- Applicants: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College; The University of New Orleans
- Inventors: Judd E. Shellito; Alistair John Ramsay; David A. Welsh; Sanbao Ruan; Yang Cai
- Web page: https://patentgrep.com/patent/US10117913B2

## CPC

- A61K 39/0002: {Fungal antigens, e.g. Trichophyton, Aspergillus, Candida}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 16/40: against enzymes
- C12N 9/48: acting on peptide bonds (3.4)
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A surface protein of the murine fungal pathogen Pneumocystis murina can be used to generate an immune response in a recipient animal or human that provides prophylactic protection and an anti-fungal activity in subjects already infected with a Pneumocystis species. Further, the disclosure provides novel polypeptides or peptides derived from the P. murina surface protein Surface Peptidase 1 (SPD-1) that are useful, alone or in combination with the SPD-1 polypeptide, in compositions and methods for the generation of an anti-Pneumocystis immune reaction by a recipient subject. The compositions and methods of the disclosure provide advantageous alternatives to available immunogenic determinants for the treatment or prevention of fungal pneumonia.

## Claims

### Claim 1

An immunogenic composition comprising an isolated Surface Peptidase 1 (SPD-1) polypeptide of Pneumocystis murina and having the sequence according to SEQ ID NO: 1 or an immunogenic fragment thereof, wherein the fragment has an amino acid sequence of at least 90% similarity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 2 and 4, and wherein the composition further comprises a pharmaceutically acceptable carrier and an adjuvant, wherein the adjuvant is MF-59, and is formulated to induce an anti-Pneumocystis immune response when administered to an animal or human recipient.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the immunogenic fragment of the SPD-1 polypeptide has an amino acid sequence SEQ ID NOs: 1, 2 or 4.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the immunogenic fragment of the SPD-1 polypeptide has the amino acid sequence SEQ ID NO: 2 or SEQ ID NO: 4.

### Claim 4 (depends on 1)

A method of generating an immune response to a Pneumocystis infection in an animal comprising administering to said animal the immunogenic composition of claim 1.

### Claim 5 (depends on 4)

The method of claim 4, wherein the Pneumocystis infection is in a human and the infectious agent is P. jirovecii.

### Claim 6 (depends on 1)

A kit comprising a container containing a therapeutic amount of an immunogenic composition according to claim 1 and instructions directing the use of the composition in generating an immune response in a recipient animal or human.